CervoMed FY2025 EPS Forecast Increased by Chardan Capital

Key Points

• Chardan Capital has raised its FY2025 earnings per share (EPS) estimate for CervoMed Inc. to ($2.56), reflecting a slight improvement from the previous estimate of ($2.57), and maintains a "Buy" rating with a price target of $15.00.
• CervoMed reported a quarterly EPS of ($0.70), which was below consensus estimates of ($0.57), but its revenue of $1.76 million surpassed analysts' expectations.
• Institutional investors own 25.15% of CervoMed, with several large firms increasing their positions in the company recently, indicating growing confidence in its future prospects.

CervoMed Inc. (NASDAQ:CRVO - Free Report) - Research analysts at Chardan Capital lifted their FY2025 earnings per share estimates for CervoMed in a report released on Monday, August 11th. Chardan Capital analyst D. Gataulin now expects that the company will post earnings of ($2.56) per share for the year, up from their previous forecast of ($2.57). Chardan Capital has a "Buy" rating and a $15.00 price target on the stock. The consensus estimate for CervoMed's current full-year earnings is ($1.88) per share. Chardan Capital also issued estimates for CervoMed's FY2026 earnings at ($1.15) EPS.

CervoMed (NASDAQ:CRVO - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.13). The firm had revenue of $1.76 million during the quarter, compared to analyst estimates of $1.45 million. CervoMed had a negative net margin of 290.72% and a negative return on equity of 59.15%.

A number of other brokerages have also recently issued reports on CRVO. Canaccord Genuity Group boosted their price objective on shares of CervoMed from $21.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. D. Boral Capital raised their price target on shares of CervoMed from $15.00 to $31.00 and gave the stock a "buy" rating in a research note on Monday. Finally, Roth Capital restated a "buy" rating and issued a $16.00 price objective (down previously from $20.00) on shares of CervoMed in a report on Tuesday, August 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $23.71.

CervoMed Stock Down 3.6%

CRVO traded down $0.3490 during trading on Thursday, hitting $9.4810. The company's stock had a trading volume of 69,539 shares, compared to its average volume of 2,057,680. The firm's 50 day moving average price is $7.78 and its two-hundred day moving average price is $7.28. The stock has a market capitalization of $87.70 million, a price-to-earnings ratio of -3.67 and a beta of -0.79. CervoMed has a 12 month low of $1.80 and a 12 month high of $20.63.

Hedge Funds Weigh In On CervoMed

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Woodline Partners LP bought a new position in shares of CervoMed during the 4th quarter worth approximately $175,000. Rhumbline Advisers grew its position in CervoMed by 35.5% during the first quarter. Rhumbline Advisers now owns 5,830 shares of the company's stock valued at $53,000 after buying an additional 1,526 shares during the period. BNP Paribas Financial Markets purchased a new stake in CervoMed during the fourth quarter worth about $32,000. Citizens Financial Group Inc. RI bought a new position in shares of CervoMed during the 1st quarter valued at approximately $244,000. Finally, Nuveen Asset Management LLC lifted its stake in CervoMed by 113.6% in the fourth quarter. Nuveen Asset Management LLC now owns 41,569 shares of the company's stock valued at $97,000 after purchasing an additional 22,104 shares during the last quarter. Institutional investors own 25.15% of the company's stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.